Chugai, Eisai, SoftBank, Takeda and Celgene have contributed to healthcare venture firm Catalys Pacific’s inaugural fund, which has a target size of $100m.
Japan-based venture capital firm Catalys Pacific officially launched a $100m healthcare fund on Monday backed by life sciences companies Celgene, Chugai Pharmaceutical, Eisai and Takeda Pharmaceutical.
Internet and telecommunications conglomerate SoftBank has also provided capital for the fund. Catalys has not confirmed whether it has reached the $100m target, indicated in a regulatory filing in March 2019 that revealed the firm had so far secured $80m.
Catalys will focus on the healthcare sector, and will particularly seek out technologies…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
